fda glp-1 warning letters november 2025 Alert: Endocrinology Drug Recalls and Approvals FDA issued 25 warning letters

320, Dec

Key Pricing Factors: Research & Development: The price of Semaglutide GLP-1 reflects the significant investment in clinical trials and regulatory approvals required to ensure its safety and effectiveness for weight loss

Its no surprise its often included in longevity and immune-support IV drips

In contrast, semaglutide at a dose of 2.4 mg per week for 68 weeks resulted in a 14.915.6% weight loss in non-diabetic individuals with overweight or obesity, also with an average BMI of approximately 38 [11, 12], demonstrating a stronger anti-obesity effect with semaglutide than with liraglutide

16 These molecules induce oxidative damage through unpaired valence-shell electrons that are highly unstable and reactive and have the ability to disrupt macromolecules, including proteins, lipids, carbohydrates, and nucleic acids